Thus, therapy in early RA targets aggressive biological disease alteration by regulating synovial T cells and decreasing the levels of cytokines associated with the disease.9 Current treatment options for RA‐ILD include disease‐modifying anti‐rheumatic drugs and biological anti‐TNF‐α therapies. The gene discussed is TNF; the disease is interstitial lung disease.